0
Editorials |

Long-Acting Bronchodilators Are the First-Choice Option for the Treatment of Stable COPD*

Mario Cazzola; Maria Gabriella Matera
Author and Funding Information

Affiliations: Naples, Italy
 ,  Dr. Cazzola is Consultant of Pneumology and Allergology, Department of Respiratory Medicine, A. Cardarelli Hospital, Naples, Italy. Dr. Matera is Researcher, Department of Experimental Medicine, Unit of Pharmacology, Second University, Naples, Italy.

Correspondence to: Mario Cazzola, MD, FCCP, A. Cardarelli Hospital, Department of Respiratory Medicine, Unit of Pneumology and Allergology, Via del Parco Margherita 24, 80121 Naples, Italy; e-mail mcazzola@qubisoft.it



Chest. 2004;125(1):9-11. doi:10.1378/chest.125.1.9
Text Size: A A A
Published online

Extract

A volume of published evidence sustains the role of long-acting β2-agonists in the treatment of stable COPD.15 These agents not only induce prolonged bronchodilation, but also translate this action into other health-outcome measures that relate to quality of life, such as the severity of dyspnea, exercise capacity, and exacerbations.6 Both formoterol and salmeterol are superior to ipratropium.1,34

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
COPD therapy: if two is good, is three better? Lancet 2016;388(10048):937-8.
Muscarinic Receptor Antagonists. Handb Exp Pharmacol Published online Oct 28, 2016;
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543